Oral fluid as a diagnostic tool

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 11, 2004, Pages 1273-1287

  Choo, Robin E ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Illicit drugs; Oral fluid; Saliva; Therapeutic drug monitoring

Indexed keywords

ALCOHOL; CARBAMAZEPINE; CLARITHROMYCIN; CLOBAZAM; DIAZEPAM; DIGOXIN; ESTRADIOL; ESTROGEN; ETHOSUXIMIDE; ETIRACETAM; GENTAMICIN; HYDROCORTISONE; ILLICIT DRUG; ISONIAZID; LAMOTRIGINE; METOPROLOL; MOXIFLOXACIN; NITRAZEPAM; OFLOXACIN; OXPRENOLOL; PHENYTOIN; PRIMIDONE; PROCAINAMIDE; PROGESTERONE; SULFANILAMIDE; TESTOSTERONE; THEOPHYLLINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID;

BLOOD LEVEL; BREAST CANCER; CELIAC DISEASE; CUSHING SYNDROME; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SALIVA LEVEL; EMOTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; GASTRITIS; HELICOBACTER PYLORI; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HORMONE DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERIALS HANDLING; MEASLES; MEASLES VIRUS; NON INVASIVE MEASUREMENT; OSMOLALITY; OVULATION; PATIENT COMPLIANCE; PEPTIC ULCER; PH; PRACTICE GUIDELINE; PREDICTION; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; RUBELLA; RUBELLA VIRUS; SALIVA ANALYSIS; SALIVATION; SJOEGREN SYNDROME; STOMACH CANCER; TECHNOLOGY; TRANSPORT KINETICS; VIRUS INFECTION;

ADULT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CLINICAL CHEMISTRY TESTS; DISEASE PROGRESSION; DRUG MONITORING; FEMALE; HEMATOLOGIC TESTS; HUMANS; INFANT; MALE; MONITORING, PHYSIOLOGIC; SALIVA; SUBSTANCE-RELATED DISORDERS;

EID: 10044228158     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.248     Document Type: Review

References (138)

1. Hold KM, de Boer D, Zuidema J, Maes RA. Saliva as an analytical tool in toxicology. Int J Drug Testing, 1995.
2. Ritschel WA, Tompson GA. Monitoring of drug concentrations in saliva: a non-invasive pharmacokinetic procedure. Methods Findings Exp Clin Pharmacol 1983;5:511-25.
3. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet 1992;23:365-79.
4. Dawes C, Macpherson LM. Effects of nine difference chewing-gums and lozenges on salivary flow rate and pH. Caries Res 1992;26:176-82.
5. Rehak NN, Cecco SA, Csako G. Biochemical composition and electrolyte balance of 'unstimulated' whole human saliva. Clin Chem Lab Med 2000;38:335-43.
6. Young D. Past and present methods and results of sugar analysis of saliva. J Dental Res 1941;20:597-626.
7. Chiou WL, Pu FS. Creatinine Vill: saliva levels of endogenous 'true' creatinine in normal subjects. Clin Pharmacol Therapeut 1979;25:777-82.
8. Monaci F, Bargagli E, Bravi F, Rottoli P. Concentrations of major elements and mercury in unstimulated human saliva. Biol Trace Element Res 2002;89:193-203.
9. Delgado LH. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet 1999;36:453-70.
10. Mucklow JC. The use of saliva in therapeutic drug monitoring. Therapeut Drug Monitor 1982;4:229-47.
11. Nagler RM, Hershkovich O, Lischinsky S, Diamond E, Reznick AZ. Saliva analysis in the clinical setting: revisiting an underused diagnostic tool. J Invest Med 2002;50:214-25.
12. McGregor JA, Jackson GM, Lachelin GCL, Goodwin TM, Artal R, Hastings C, et al. Salivary estriol as risk assessment for preterm labor: a prospective trial. Am J Obstet Gynecol 1995;173:1337-42.
13. Schmidt NA. Salivary cortisol testing in children. Issues Comprehen Ped Nurs 1997;20:183-90.
14. Kefalides PT. Saliva research leads to new diagnostic tools and therapeutic options. Ann Intern Med 1999;131:991-2.
15. Lawrence HP. Salivary markers of systemic disease: noninvasive diagnosis of disease and monitoring of general health. J Can Dental Assoc 2002;68:170-4.
16. Judd A, Parry J, Hickman M, McDonald T, Jordan L, Lewis K, et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol 2003;71:49-55.
17. Streckfus C, Bigler L, Dellinger T, Pfeifer M, Rose A, Thigpen JT. CA 15-3 and c-erbB-2 presence in the saliva of women. Clin Oral Invest 1999;3:138-43.
18. Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res 2000;6:2363-70.
19. Streckfus C, Bigler L, Tucci M, Thigpen JT. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathespsin-D, and p53 in saliva among women with breast carcinoma. Cancer Invest 2000;18:101-9.
20. Bigler L, Streckfus CF, Copeland L, Burns R, Dai X, Kuhn M, et al. The potential use of saliva to detect recurrence of disease in women with breast carcinoma. J Oral Pathol Med 2002;31:421-31.
21. Chen DX, Schwartz PE. Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990;75:701-4.
22. Boyle JO, Mao L, Brennan JA, Koch WM, Eisele DW, Saunders JR, et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 1994;168:429-32.
23. Franzmann EJ, Schroeder GL, Goodwin WJ, Weed DT, Fisher P, Lokeshwar VB. Expression of tumor markers hyaluronic acid and hyaluronidase (hyali) in head and neck tumors. Int J Cancer 2003;106:438-45.
24. Nokes DJ, Enquselassie F, Nigatu W, Vyse AJ, Cohen B, Brown DWG, et al. Has oral fluid the potential to replace serum for the evaluation of population immunity levels? A study of measles, rubella and hepatitis B in rural Ethiopia. Bull WHO 2001;79:588-95.
25. Morris MC, Edmunds WJ, Miller E, Brown DWG. Oral fluid collection by post - a pilot study of two approaches. Public Health 2002;116:113-9.
26. Castro J, Jimenez-Alonso J, Sabio JM, Rivera-Civico F, Martin-Armada M, Rodriguez MA, et al. Salivary and serum B2-microglobulin and gamma-glutamyl-transferase in patients with primary Sjogren syndrome and Sjogren syndrome secondary to systemic lupus erythematosus. Clin Chim Acta 2003;334:225-31.
27. Berra A, Sterin-Borda L, Bacman S, Borda E. Role of salivary IgA in the pathogenesis of Sjogren syndrome. Clin Immunol 2002;104:49-57.
28. Hakeem V, Fifield R, Al-Bayaty HF, Aldred MJ, Walker DM, Williams J, et al. Salivary IgA antigliadin antibody as a marker for coeliac disease. Arch Dis Child 1992;67:724-7.
29. Rujner J, Socha J, Barra E, Gregorek H, Madalinski K, Wozniewicz B, et al. Serum and salivary antigliadin antibodies and serum IgA anti-endomysium antibodies as a screening test for coeliac disease. Acta Paediatr 1996;85:814-7.
30. Marchetti P, Benzi L, Masoni A, Cecchetti P, Giannarelli R, Di Cianni G, et al. Salivary insulin concentrations in type 2 (non-insulin-dependent) diabetic patients and obese non-diabetic subjects: relationship to changes in plasma insulin levels after an oral glucose load. Diabetologia 1986;29:695-8.
31. Kahn SE, Maxwell JU, Barron JL. Salivary cortisol assessment in the evaluation of hypothalamic-pituitary-adrenal function. S Afr Med J 1984;65:843-6.
32. Koelle DM, Huang ML, Chandran B, Vieira J, Piepkorn M, Corey L. Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis 1997; 176:94-102.
33. Reilly TG, Poxon V, Sanders DSA, Elliott TSJ, Wait RP. Comparison of serum, salivary, and rapid whole blood diagnostic tests for Helicobacter pylori and their validation against endoscopy based tests. Gut 1997;40:454-8.
34. Kudo T, Egawa H, Kuzushima K, Kimura H, Morishima T, Ichiyama S. Diagnostic testing in Epstein-Barr virus infection. Clin Chem Lab Med 2001;39:789-94.
35. Sheppard C, Cohen B, Andrews N, Surridge H. Development and evaluation of an antibody capture ELISA for detection of IgG to Epstein-Barr virus in oral fluid samples. J Virol Methods 2001;93:157-66.
36. Crawford DH. Biology and disease associations of Epstein-Barr virus. Phil Trans R Soc Lond B 2001; 356:461-73.
37. Castro M, Elias PCL, Martinelli CE, Antonini SRR, Santiago L, Moreira AC. Salivary cortisol as a tool for physiological studies and diagnostic strategies. Braz J Med Biol Res 2000;33:1171-5.
38. Scully C. HIV topic update: salivary testing for antibodies. Oral Dis 1997;3:212-5.
39. Emmons W. Accuracy of oral specimen testing for human immunodeficiency virus. Am J Med 1997; 102:15-20.
40. Malamud D. Oral diagnostic testing for detecting human immunodeficiency virus-1 antibodies: a technology whose time has come. Am J Med 1997;102:9-14.
41. Chatzipantazi P, Roy KM, Cameron SO, Goldberg D, Welbury R, Bagg J. The feasibility and acceptability of collecting oral fluid from healthy children for anti-HCV testing. Arch Dis Child 2004;89:185-7.
42. Bello PY, Pasquier C, Gourney P, Puel J, Isopet J. Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies. Eur J Clin Microbiol Infect Dis 1998;17:570-2.
43. Elsana S, Sikuler E, Yaari A, Shemer-Avni Y, Abu-Shakra M, Buskila D, et al. HCV antibodies in saliva and urine. J Med Virol 1998;55:24-7.
44. Al-Bayaty HF, Aldred MJ, Walker MD, Newcombe RG, Swift G, Smith PM, et al. Salivary and serum antibodies to gliadin in the diagnosis of celiac disease. J Oral Therapeut Pharmacol 1989;18:578-81.
45. Al Za'Abi M, Deleu D, Batchelor C. Salivary free concentrations of anti-epileptic drugs: an evaluation in a routine clinical setting. Acta Neurol Belg 2003;103:19-23.
46. Soldin OP, Soldin SJ. Review: therapeutic drug monitoring in pediatrics. Therapeut Drug Monitor 2002;24:1-8.
47. Berkovitch M, Bistritzer T, Aladjem M, Burtin P, Dagan T, Chen-Levi Z, et al. Clinical relevance of therapeutic drug monitoring of digoxin and gentamycin in the saliva of children. Therapeut Drug Monitor 1998;20:253-6.
48. Cordonnier J, Van den Heede M, Heyndrickx A. Saliva concentrations of disopyramide cannot substitute the drug's plasma concentrations. J Anal Toxicol 1987; 11:179-81.
49. Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med 2002;40:986-93.
50. Cotariu D, Zaidman JL. Developmental toxicity of valproic acid. Life Sci 1991;48:1341-50.
51. Pisani FD, Di Perri RG. Intravenous valproate: effects on plasma and saliva phenytoin levels. Neurology 1981;31:467-70.
52. McAuliffe JJ, Sherwin AL, Leppik IE, Fayle SA, Pippenger CE. Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology 1977; 27:409-13.
53. Horning MG, Brown L, Nowlin J, Lertratatanangkoon K, Kellaway P, Zion TE. Use of saliva in therapeutic drug monitoring. Clin Chem 1977;23:157-64.
54. Siegel IA. The role of saliva in drug monitoring. Ann NY Acad Sci 1993;694:86-90.
55. Grim SA, Ryan M, Miles MV, Tang PH, Strawsburg RH, deGrauw TJ, et al. Correlation of levetiracetam concentrations between serum and saliva. Therapeut Drug Monitor 2003;25:61-6.
56. Miles MV, Tang PH, Glauser TA, Ryan MA, Grim SA, Strawsburg RH, et al. Topiramate concentration in saliva: an alternative to serum monitoring. Pediatric Neurol 2003;29:143-7.
57. Tsiropoulos I, Kristensen O, Klitgaard NA. Saliva and serum concentration of lamotrigine in patients with epilepsy. Therapeut Drug Monitor 2000;22:517-21.
58. Ryan M, Grim SA, Miles MV, Tang PH, Fakhoury TA, Strawsburg RH, et al. Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy 2003;23:1550-7.
59. deGier JJ, Hart BJT, Wilderink PF, Nelemans FA. Comparison of plasma and saliva levels of diazepam. Br J Clin Pharmacol 1980;10:151-5.
60. Giles HG, Miller R, Macleod SM, Sellers EM. Diazepam and N-desmethyldiazepam in saliva of hospital inpatients. J Clin Pharmacol 1980;20:71-6.
61. Hallstrom C, Lader MH, Curry SH. Diazepam and N-desmethyldiazepam concentrations in saliva, plasma and CSF. Br J Clin Pharmacol 1980;9:333-9.
62. Kangas L, Allonen H, Lammintausta R, Salonen M, Pekkarinen A. Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. Acta Pharmacol Toxicol 1979;45:20-4.
63. Hart BJ, Wilting J, De Gier JJ. The stability of benzodiazepines in saliva. Methods Find Exp Clin Pharmacol 1988;10:21-6.
64. Gurumurthy P, Rahman F, Narayana AS, Sarma GR. Salivary levels of isoniozid and rifampicin in tuberculous patients. Tubercle 1990;71:29-33.
65. Ofoefule SI, Obodo CE, Orisakwe CE, Afonne JO, Ilondu NA, Agbasi PU, et al. Salivary and urinary excretion and plasma-saliva concentration ratios of isoniazid in the presence of co-administered ciprofloxacin. Am J Therapeut 2002;9:15-8.
66. Immanuel C, Hemanthkumar AK, Gurumurthy P, Venkatesan P. Dose related pharmacokinetics of ofloxacin in healthy volunteers. Int J Tuberc Lung Dis 2002; 6:1017-22.
67. Warlich R, Korting HC, Schafer-Korting M, Mutschler E. Multiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteers. Antimicrob Agents Chemother 1990;34:78-81.
68. Berkovitch M, Goldman M, Silverman R, Chen-Levi Z, Greenberg R, Marcus O, et al. Therapeutic drug monitoring of once daily gentamycin in serum and saliva of children. Eur J Pediatr 2000;159:697-8.
69. Bennett GA, Davies E, Thomas P. Is oral fluid analysis as accurate as urinalysis in detecting drug use in a treatment setting? Drug Alcohol Depend 2003;72:265-9.
70. Smith M, Whitehead E, O'Sullivan G, Reynolds F. A comparison of serum and saliva paracetamol concentrations. Br J Clin Pharmacol 1991;31:553-5.
71. Hahn TW, Mogensen T, Lund C, Schouenborg L, Rasmussen M. High-dose rectal and oral acetaminophen in postoperative patients - serum and saliva concentrations. Acta Anaesthesiol Scand 2000;44:302-6.
72. Kennedy JM, Tyers NM, Davey AK. The influence of morphine on the absorption of paracetamol from various formulations in subjects in the supine position, as assessed by TDx measurement of salivary paracetamol concentrations. J Pharm Pharmacol 2003;55:1345-50.
73. Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol 2002;94:39-44.
74. Slavik M, Wu J, Riley C. Salivary excretion of anticancer drugs. Ann NY Acad Sci 1993;694:319-21.
75. Svojanovsky SR, Egodage KL, Wu J, Slavik M, Wilson GS. High sensitivity ELISA determination of taxol in various human biological fluids. J Pharmaceut Biomed Anal 1999;20:549-55.
76. Jansman FG, Coenen JL, De Graaf JC, Tobi H, Sleijfer DT, Brouwers JR. Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid. Anticancer Res 2002;22: 3449-56.
77. Joulia JM, Pinguet F, Ychou M, Duffour J, Astre C, Bressolle F. Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with mestastic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. Eur J Cancer 1999; 35:296-301.
78. Takahashi T, Fujiwara Y, Sumiyoshi H, Isobe T, Yamaoka N, Tamakido M. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients. Cancer Chemother Pharmacol 1997;40:449-52.
79. van Warmerdam LJ, van Tellingen O, ten Bokkel Huinink WW, Rodenhuis S, Maes RA, Bijnen JH. Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements? Therapeut Drug Monitor 1995;17:465-70.
80. Boucaud M, Pinguet F, Culine S, Poujol S, Astre C, Gomeni R, et al. Modeling plasma and saliva topotecan concentration time course using a population approach. Oncol Res 2003;13:211-9.
81. Babalola CP, Balaji OO, Ogunbona FA, Dixon PA. Relationship between plasma and saliva quinine levels in humans. Therapeut Drug Monitor 1996;18:30-3.
82. Spencer EK, Campbell MA, P, Perry R, Choroco MC, Padron-Gayol M, Small AM. Saliva and serum lithium monitoring in hospitalized children. Psychopharmacol Bull 1990;26:239-43.
83. Ben-Aryeh H, Shalev A, Szargel R, Laor A, Laufer D, Gutman D. The salivary flow rate and composition of whole and parotid resting and stimulated saliva in young and old healthy subjects. Biochem Med Metabol Biol 1986;36:260-5.
84. McKeage MJ, Maling TJB. Saliva lithium: a poor predictor of plasma and erythrocyte levels. N Zealand Med J 1989;102:559-60.
85. Obach R, Borja J, Valles JM, Torrent J, Izquierdo I, Jane F. Lack of correlation between lithium pharmacokinetic parameters obtained from plasma and saliva. Therapeut Drug Monitor 1988;10:265-8.
86. Moody JP. Biologic variation of serum and salivary lithium. Therapeut Drug Monitor 1999;21:97-101.
87. Baumann P, Tinguely D, Koeb L, Schopf J, Le PK. On the relationship between free plasma and saliva amitriptyline and nortriptyline. Int Pharmacopsychiat 1982; 17:136-46.
88. Kidwell DA. Discussion: caveats in testing for drugs of abuse. NIDA Res Monogr 1992;117:98-120.
89. Cone EJ, Presley L, Lehrer M, Seiter W, Smith M, Kardos KW, et al. Oral fluid testing for drugs of abuse: positive prevalence rates by Intercept Immunoassay Screening and GC-MS-MS confirmation and suggested cutoff concentrations. J Anal Toxicol 2002;26:541-6.
90. Penttila A, Karhunen PJ, Pikkarainen J. Alcohol screening with the alcoscan test strip in forensic praxis. Forensic Sci Int 1990;44:43-8.
91. Royston JP. Correlation of ethanol concentrations in blood and saliva. Clin Sci 1980;58:179-81.
92. Girja KP, Sundharam BS, Krishnan PA, Devi CS. Biochemical changes of saliva in tobacco chewers, tobacco smokers, alcohol consumers, leukoplakia and oral cancer patients. Indian J Dental Res 2002;13:102-7.
93. Simpson T, Murphy N, Peck DF. Saliva alcohol concentrations in accident and emergency attendances. Emerg Med 2001;18:250-4.
94. Cone EJ, Jenkins AJ. Saliva drug analysis. In: Wong SHY, Sunshine I, editors. Handbook of analytical therapeutic drug monitoring and toxicology. New York: CRC Press, 1997:303-33.
95. Cone EJ. New developments in biological measures of drug prevalence. NIDA Res Monogr 1997;167:108-29.
96. Wan SH, Matin SB, Azarnoff DL. Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Therapeut 1978;23:585-90.
97. Navarro M, Pichini S, Farre M, Ortuno J, Roset PN, Segura J, et al. Usefulness of saliva for measurement of 3,4-methylenedioxymehamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. Clin Chem 2001;47:1788-95.
98. Mas M, Farre M, de La Torre R, Roset PN, Ortuno J, Seguar J, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Therapeut 1999;290:136-45.
99. Samyn N, De Boeck G, Wood M, Lamers CTJ, De Waard D, Brookhuis KA, et al. Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sci Int 2002;128:90-7.
100. Schepers RJ, Oyler JM, Joseph RE Jr, Cone EJ, Moolchan ET, Huestis MA. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem 2003;49:121-32.
101. Schramm W, Smith RH, Craig PA, Kidwell DA. Drugs of abuse in saliva: a review. J Anal Toxicol 1992;16:1-9.
102. Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol 2001;25:289-303.
103. Jehanli A, Brannan S, Moore L, Spiehler VR. Blind trials of an onsite saliva drug test for marijuana and opiates. J Forensic Sci 2001;46:1214-20.
104. Manno BR, Manno JE. The marijuana dilemma: implications of recent research into the pharmacokinetics, psychomotor effects and cardiovascular actions of THC. In: Winek CL, Shanor SP, editors. Toxicology annual 1974. New York: Marcel Dekker, 1976:129-50.
105. Gronholm M, Lillsunde P. A comparison between onsite immunoassay drug-testing devices and laboratory results. Forensic Sci Int 2001;121:37-46.
106. Samyn N, van Haeren C. On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users. Int J Legal Med 2000;113:150-4.
107. Kato K, Hillsgrove M, Weinhold L, Gorelick DA, Darwin WD, Cone EJ. Cocaine and metabolite excretion in saliva under stimulated and nonstimulated conditions. J Anal Toxicol 1993;17:338-41.
108. Stillman R, Jones RT, Moore D, Walker J, Welm S. Improved performance 4 hours after cocaine. Psychopharmacology 1993;110:415-20.
109. Moolchan ET, Cone EJ, Wstadik A, Huestis MA, Preston KL. Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: plasma and saliva analysis. J Anal Toxicol 2000;24:458-66.
110. Jufer RA, Wstadik A, Walsh SL, Levine BS, Cone EJ. Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. J Anal Toxicol 2000;24:467-77.
111. Presley L, Lehrer M, Seiter W, Hahn D, Rowland B, Smith M, et al. High prevalence of 6-acetylmorphine in morphine-positive oral fluid specimens. Forensic Sci Int 2003;133:22-5.
112. Kaltenbach K, Finnegan LP. The influence of the neonatal abstinence syndrome on mother-infant interaction. In: Anthony EJ, Chiland C, editors. The child in his family. New York: John Wiley & Sons, 1988:223-50.
113. Jenkins AJ, Oyler JM, Cone EJ. Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. J Anal Toxicol 1995;19:359-74.
114. Bermejo AM, Lucas ACS, Tabernero MJ. Saliva/plasma ratio of methadone and EDDP. J Anal Toxicol 2000;24:70-2.
115. O'Neal CL, Crouch DJ, Rollins DE, Fatah A, Cheever ML. Correlation of saliva codeine concentrations with plasma concentrations after oral codeine administration. J Anal Toxicol 1999;23:452-9.
116. O'Neal CL, Crouch DL, Rollins DE, Fatah AA. The effects of collection methods on oral fluid codeine concentrations. J Anal Toxicol 2000;24:536-42.
117. Morabia A, Bernstein MS, Curtin F, Berode M. Validation of self-reported smoking status by simultaneous measurement of carbon monoxide and salivary thiocyanate. Prev Med 2001;32:82-8.
118. Kauert G. Detection of drugs in saliva versus blood. Blutalkohol 2000;37:76-83.
119. Verstraete A. www.ROSITA.org.
120. Edgar WM. Saliva: its secretion, composition and functions. Br Dental J 1992;172:305-6.
121. Jusko WJ, Gerbracht L, Golden LH, Koup JR. Digoxin concentrations in serum and saliva. Res Commun Chem Pathol Pharmacol 1975;10:189-92.
122. Vining RF, McGinley RA. Hormones in saliva. Crit Rev Clin Lab Sci 1986;23:95-146.
123. Spiers CF. Oral absorption and secretion of drugs. Br J Clin Pharmacol 1977;4:97-100.
124. Paton RD, Logan RW. Salivary drug measurement: a cautionary tale. Lancet 1986;2(8519):1340.
125. Chang K, Chiou WL. Interactions between drugs and saliva-stimulating parafilm and their implications in measurements of saliva drug levels. Res Commun Chem Pathol Pharmacol 1976;13:357-60.
126. Dawes C. Considerations in the development of diagnostic tests on saliva. Ann NY Acad Sci 1993;694:265-9.
127. De Giovanni N, Fucci N, Chiarotti M, Scarlata S. Cozart Rapiscan System: our experience with saliva tests. J Chromatogr B Analyt Technol Biomed Life Sci 2002;773:1-6.
128. Barnes AJ, Kim I, Schepers R, Moolchan ET, Wilson L, Cooper G, et al. Sensitivity, specificity, and efficiency in detecting opiates in oral fluid with the Cozart opiate microplate EIA and GC-MS following controlled codeine administration. J Anal Toxicol 2003;27:402-6.
129. Dabbs JM Jr, Jurkovic GJ, Frady RL. Salivary testosterone and cortisol among late adolescent male offenders. J Abnorm Child Psychol 1991;19:469.
130. Nokes DJ, Enquselassie F, Vyse A, Nigatu W, Cutts FT, Brown DWG. An evaluation of oral-fluid collection devices for the determination of rubella antibody status in a rural Ethiopian community. Trans R Soc Trop Med Hyg 1998;92:679-85.
131. Barrett C, Good C, Moore C. Comparison of point-of-collection screening of drugs of abuse in oral fluid with a laboratory-based urine screen. Forensic Sci Int 2001;122:163-6.
132. Mura P, Kintz P, Samyn N, Vincent F, Mauco G. Application of drugwipe in alternative specimens. www.vv.se/trafp6sak/t2000/806.pdf 2000:1-7.
133. Chang HP, Anderson GC, Wood CE. Feasible and valid saliva collection for cortisol in transitional newborn infants. Nursing Res 1995;44:117-9.
134. Riad-Fahmy D, Read GF, Walker RF. Salivary steroid assays for assessing variation in endocrine activity. J Steroid Biochem 1983;19:265-72.
135. Kiess W, Meidert A, Dressendorfer RA, Schriever K, Kessler U, Konig A, et al. Salivary cortisol levels throughout childhood and adolescence: relation with age, pubertal stage, and weight. Pediatr Res 1995;37:502-6.
136. Gorodischer R, Koren G. Salivary excretion of drugs in children: theoretical and practical issues in therapeutic drug monitoring. Dev Pharmacol Therapeut 1992; 19:161-77.
137. Bales CW, Freeland-Graves JH, Askey S, Behmardi F, Pobocik RS, Fickel JJ, et al. Zinc, magnesium, copper, and protein concentrations in human saliva: age- and sex-related differences. Am J Clin Nutr 1990;51:462-9.
138. Gugilla SR, Boinpally RR, Bolla SM, Devaraj R. Influence of menstrual cycle on the pharmacokinetics of paracetamol through salivary compartment in healthy subjects. Therapeut Drug Monitor 2002;24:497-501.